Canaccord raised the firm’s price target on Globus Medical (GMED) to $115 from $112 and keeps a Buy rating on the shares. The firm said the company posted an impressive Q4, with results above its preliminary results announced in January, growing 24.7% reported, with legacy sales up 10.6% reported and day-adjusted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical: Sustained Outperformance, Margin Expansion, and Acquisition Synergies Support Buy Rating
- Buy Rating Reaffirmed on Strong Q4 Performance, Raised 2026 EPS Outlook, and Robust Spine & Robotics Growth Prospects
- Globus Medical price target raised to $123 from $118 at Barclays
- Globus Medical reports Q4 EPS $1.28, consensus 96c
- Globus Medical raises FY26 EPS view to $4.40-$4.50 from $4.30-$4.40